175 related articles for article (PubMed ID: 20347540)
1. Hepatobiliary transit times of gadoxetate disodium (Primovist®) for protocol optimization of comprehensive MR imaging of the biliary system--what is normal?
Ringe KI; Husarik DB; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2011 Aug; 79(2):201-5. PubMed ID: 20347540
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
3. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
4. Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.
Ringe KI; Hinrichs J; Merkle EM; Weismüller TJ; Wacker F; Meyer BC
J Magn Reson Imaging; 2014 Jul; 40(1):106-12. PubMed ID: 24923477
[TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
6. Value of gadoxetate biliary transit time in determining hepatocyte function.
Wu J; Li H; Lin Y; Chen Z; Zhong Q; Gao H; Fu L; Sandrasegaran K
Abdom Imaging; 2015 Jan; 40(1):95-101. PubMed ID: 25056714
[TBL] [Abstract][Full Text] [Related]
7. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
8. Gd-EOB-DTPA as a functional MR cholangiography contrast agent: imaging gallbladder filling in patients with and without hepatobiliary dysfunction.
Smith AD; Veniero JC
J Comput Assist Tomogr; 2011; 35(4):439-45. PubMed ID: 21765298
[TBL] [Abstract][Full Text] [Related]
9. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers.
Tamada T; Ito K; Sone T; Kanki A; Sato T; Higashi H
Eur J Radiol; 2011 Dec; 80(3):e207-11. PubMed ID: 20869827
[TBL] [Abstract][Full Text] [Related]
10. Functional MR cholangiography of the cystic duct and sphincter of Oddi using gadoxetate disodium: is a 30-minute delay long enough?
Corwin MT; Lamba R; McGahan JP
J Magn Reson Imaging; 2013 Apr; 37(4):993-8. PubMed ID: 23001618
[TBL] [Abstract][Full Text] [Related]
11. Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI.
Péporté AR; Sommer WH; Nikolaou K; Reiser MF; Zech CJ
Eur J Radiol; 2013 Mar; 82(3):e101-6. PubMed ID: 23159401
[TBL] [Abstract][Full Text] [Related]
12. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
[TBL] [Abstract][Full Text] [Related]
13. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
[TBL] [Abstract][Full Text] [Related]
14. Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
Yonetomi D; Kadosawa T; Miyoshi K; Nakao Y; Homma E; Hanazono K; Yamada E; Nakamura K; Ijiri A; Minegishi N; Maetani S; Hirayama K; Taniyama H; Nakade T
Vet Radiol Ultrasound; 2012; 53(4):371-80. PubMed ID: 22548505
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
16. Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate.
Schmid-Tannwald C; Herrmann K; Oto A; Panteleon A; Reiser M; Zech C
Acta Radiol; 2012 Nov; 53(9):961-5. PubMed ID: 23024179
[TBL] [Abstract][Full Text] [Related]
17. Functional magnetic resonance cholangiography with Gd-EOB-DTPA: a study in healthy volunteers.
Lee SW; Cha SH; Chung HH; Kim KH; Yeom SK; Seo BK; Je BK; Kim BH
Magn Reson Imaging; 2014 May; 32(4):385-91. PubMed ID: 24529920
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
19. Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?
Bashir MR; Husarik DB; Ziemlewicz TJ; Gupta RT; Boll DT; Merkle EM
J Magn Reson Imaging; 2012 Mar; 35(3):611-6. PubMed ID: 22034383
[TBL] [Abstract][Full Text] [Related]
20. Detection of active bile leak with Gd-EOB-DTPA enhanced MR cholangiography: comparison of 20-25 min delayed and 60-180 min delayed images.
Cieszanowski A; Stadnik A; Lezak A; Maj E; Zieniewicz K; Rowinska-Berman K; Grudzinski IP; Krawczyk M; Rowiński O
Eur J Radiol; 2013 Dec; 82(12):2176-82. PubMed ID: 24012454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
